HMBD-501

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameHMBD-501

Drug Alias NameENV-501HMBD-501ENV-ONC-501

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload

Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I inhibitors

TargetsReceptor tyrosine-protein kinase erbB-3DNA topoisomerase I

Therapy Area/IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesHummingbird Bioscience

China Registration ClassN/A

Develop Information

Active CompaniesHummingbird Bioscience

Inactive CompaniesN/A

Active IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A